Evidence map›Paper›PMID 34374108›Full record

Trial reportAndrologia2021

Impact of duloxetine on male fertility: A randomised controlled clinical trial.

Nahid Punjani, Caroline Kang, Ryan Flannigan, Phil Bach, Margaret Altemus, James H Kocsis, Alan Wu, Hudson Pierce, Peter N Schlegel

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Andrologia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 11 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Nahid PunjaniDepartment of Urology, Weill Cornell Medicine, New York, NY, USA.ORCID https://orcid.org/0000-0003-2127-0483
Caroline KangDepartment of Urology, Weill Cornell Medicine, New York, NY, USA.
Ryan FlanniganDepartment of Urology, Weill Cornell Medicine, New York, NY, USA.
Phil BachDepartment of Urology, Weill Cornell Medicine, New York, NY, USA.
Margaret AltemusDepartment of Psychiatry, Weill Cornell Medicine, New York, NY, USA.
James H KocsisDepartment of Psychiatry, Weill Cornell Medicine, New York, NY, USA.
Alan WuDivision of Biostatistics and Epidemiology, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Hudson PierceDepartment of Urology, Weill Cornell Medicine, New York, NY, USA.
Peter N SchlegelDepartment of Urology, Weill Cornell Medicine, New York, NY, USA.ORCID https://orcid.org/0000-0002-7129-8137
Cornell University · US

Funding

Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
Small RNA Pathways in Mammalian GametogenesisP50HD076210 · NICHD · CORNELL UNIVERSITY · PI SCHLEGEL, PETER N · 2014 to 2018
$7.4M
Funding provided by Weill Cornell Medical College Clinical & Translational Science Center (NIH/NCATS UL1TR002384).NCATS NIH HHS UL1 TR002384NICHD NIH HHS P50 HD076210NP, CK, RF, and PB were supported in part by the Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust.
6 · The paper itself

Abstract

This study assessed the impact of duloxetine (serotonin and norepinephrine reuptake inhibitor) on semen parameters, sperm DNA fragmentation and serum hormones. We performed a double-blind, placebo-controlled, randomised clinical trial of duloxetine 60mg or placebo daily for 6 weeks (5 weeks full dose and 1 week taper). The primary outcome was the proportion of men with abnormal DNA fragmentation during and after duloxetine administration. Secondary outcomes were changes in semen parameters and hormones on treatment (2 and 6 weeks) and after discontinuation (8 and 10 weeks). Sixty-eight healthy males aged 18-65 were included. Duloxetine was not associated with an increase in the proportion of participants with abnormal sperm DNA fragmentation terminal deoxynucleotidyl transferase dUTP nick-end labelling scores (>25%) on treatment (p = 0.09) or after treatment (p = 0.56), nor did median sperm DNA fragmentation increase on treatment. Compared with placebo, there were no changes in bulk semen parameters during treatment. Limited changes in hormonal values were detected. This first published human study of a serotonin and norepinephrine reuptake inhibitor on male fertility revealed no clinically meaningful effects on sperm DNA fragmentation, semen parameters or serum hormones. Duloxetine, and possibly other serotonin and norepinephrine reuptake inhibitors, may be considered for men desiring fertility who require antidepressant treatment.

Indexed as

Antidepressive AgentsSpermatozoaDNA FragmentationDouble-Blind MethodDuloxetine HydrochlorideFertilityHumansMaleSelective Serotonin Reuptake InhibitorsAntidepressive AgentsDuloxetine HydrochlorideSelective Serotonin Reuptake InhibitorsDNA fragmentationduloxetinesemen parametersSNRIs

Identifiers

PMID34374108
PMCPMC8487983
OpenAlexW3192373898

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.